Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by cdk4 and filamin a

HIGHLIGHTS

• who: S. Mouron from the (UNIVERSITY) have published the research work: Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A, in the Journal: (JOURNAL) of 11/01/2022
• what: As the authors show below, this fact is of key relevance, since paclitaxel exerts its antitumour effects by stabilizing and thereby blocking microtubule polymerization/depolymerization dynamics26-28. In this first step, the authors aimed to detect which of the 11 potential biomarkers maintained an association with the response to paclitaxel after the mass-spectrometry-to-immunohistochemistry . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.